VRCA earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -3.66. Updated 2026-07-23.
Verrica Pharmaceuticals (VRCA) Research Hub
Verrica Pharmaceuticals (VRCA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.91 USD (-2.96%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.66, market cap 0.06B. This hub links to the full technical, earnings and options research available for VRCA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.91 USD (-2.96%) |
| 52-week range | 4.64 USD – 7 USD |
| Trend regime | Range |
| 14-day RSI | 46.9 (Neutral) |
| Trailing P/E | -3.66 |
| Market cap | 0.06B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for VRCA
Covered Call on VRCA: how it works, illustrative setup around the real 4.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VRCA: how it works, illustrative setup around the real 4.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VRCA: how it works, illustrative setup around the real 4.91 USD price, max profit/loss, breakeven and when to use it. Educational.
VRCA technical analysis: range, last 4.91 USD, RSI 46.9, 52w range 4.64 USD–7 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VRCA in?
Verrica Pharmaceuticals (VRCA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VRCA in an uptrend or downtrend?
As of 2026-09-11, VRCA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VRCA's trailing P/E ratio?
VRCA's trailing P/E is -3.66, with a market cap of 0.06B. See the earnings research page for full valuation detail.
When does VRCA next report earnings?
VRCA is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.41 USD.